Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
Table 1
HMGB1 and other biomarkers of patients with ovarian cancer treated with peptide vaccination†.
Case
Overall survival (months)
IgG response
CTL response
Epitope spreading
HMGB1‡ (ng/mL)
MDSC‡ (%)
SAA‡ (mg/dL)
CRP‡ (mg/dL)
IL-6‡ (pg/mL)
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
F-018
19.1
No
No
No
<2.5
2.7
NC
0.3
0.6
I
10.5
5.2
D
0.3
0.4
NC
2
11
I
FOV-003
20.0
Yes
Yes
Yes
5.9
<2.5
D
0.2
0.3
NC
1.5
19.5
I
0.0
0.9
I
0
0
NC
FOV-004
5.3
Yes
Yes
Yes
10.6
<2.5
D
0.6
0.5
NC
3.2
11.6
I
0.1
0.3
I
2
3
NC
FOV-005
11.4
Yes
Yes
Yes
5.7
<2.5
D
0.6
0.5
NC
0.4
12.7
I
0.2
0.8
I
0
2
I
FOV-006
34.7
Yes
Yes
Yes
<2.5
2.9
NC
0.5
0.5
NC
0.7
1.1
NC
0.1
0.2
I
0
0
NC
FOV-008
14.1
Yes
Yes
No
4.3
2.8
NC
0.1
0.1
NC
2.4
18.8
I
0.1
0.9
I
0
0
NC
FOV-009
8.1
Yes
Yes
Yes
4.5
3.9
NC
0.5
0.4
NC
20.4
20.8
NC
0.7
1.0
NC
0
0
NC
FOV-010
>69.7
Yes
Yes
Yes
<2.5
<2.5
NC
0.1
0.3
I
0.3
7.9
I
0.0
0.5
I
0
0
NC
FOV-012
16.1
Yes
Yes
No
<2.5
<2.5
NC
1.1
1.6
NC
6.3
1.7
D
0.1
0.5
I
0
0
NC
FOV-013
4.0
No
Yes
No
<2.5
3.7
NC
0.1
0.1
NC
11.8
11.8
NC
0.9
0.9
NC
10
23
I
FOV-014
32.2
Yes
Yes
Yes
5.0
3.5
NC
0.3
0.3
NC
12.8
14.8
NC
0.1
0.3
I
0
0
NC
FOV-015
10.7
Yes
No
No
4.0
10.4
I
1
1.2
NC
2.9
14.9
I
0.6
0.9
NC
0
0
NC
FOV-016
29.5
Yes
Yes
No
3.8
9.2
I
0.6
0.4
NC
12.1
13.8
NC
1.0
0.9
NC
6
12
I
FOV-019
>61.3
Yes
No
Yes
2.7
4.9
NC
0.6
0.4
NC
1.4
5.6
I
0.1
0.6
I
0
0
NC
FOV-022
22.0
Yes
Yes
No
4.6
3.2
NC
0.5
—§
1.8
3.6
I
0.4
0.1
D
0
0
NC
FOV-023
16.8
Yes
Yes
Yes
6.5
3.5
NC
0.1
0.2
I
13.8
11.9
NC
1.5
2.3
NC
2
15
I
FOV-024
8.7
No
No
No
<2.5
6.1
I
0.2
0.1
D
8.9
11.8
NC
0.8
2.3
I
0
17
I
FOV-026
>45.7
Yes
Yes
Yes
3.1
5.2
NC
NC
4.2
5.5
NC
0.1
0.1
NC
0
0
NC
FOV-027
36.9
Yes
Yes
Yes
12.8
7.8
NC
0.2
0.6
I
2.6
4.8
NC
0.0
0.6
I
0
0.5
I
FOV-028
>42.7
Yes
Yes
No
17.4
<2.5
D
0.2
0.7
I
0.3
0.4
NC
0.3
0.0
D
1.2
1.1
NC
FOV-030
22.0
Yes
Yes
Yes
8.5
12.5
NC
0.4
0.5
NC
6.1
22.5
I
0.4
4.1
I
0
8
I
FOV-031
19.6
Yes
No
Yes
4.2
4.7
NC
0.3
0.3
NC
8.2
9.5
NC
0.1
0.2
I
0
0
NC
FOV-032
12.6
Yes
Yes
Yes
4.2
3.8
NC
0.6
0.3
D
0.3
5.2
I
0.2
2.2
I
0
7.2
I
FOV-033
26.9
Yes
Yes
Yes
<2.5
3.5
NC
0.4
0.5
NC
1.6
12.9
I
0.1
1.8
I
0
2.7
I
FOV-034
26.8
Yes
No
Yes
12.2
6.7
NC
0.7
0.6
NC
0.6
0.7
NC
0.1
0.3
I
0
0
NC
FOV-036
24.0
Yes
Yes
Yes
5.4
4.2
NC
0.2
0.2
NC
1.8
19.3
I
1.9
4.4
I
0.9
26.2
I
FOV-037
4.6
No
No
No
7.3
2.6
D
0.7
0.4
NC
0.7
15.8
I
1.4
4.4
I
4.6
19.8
I
FOV-038
7.9
No
No
No
15.1
18.6
NC
1.4
1.1
NC
11.6
20.9
NC
1.7
3.6
I
4.5
14.9
I
FOV-039
>10.3
Yes
No
No
3.0
<2.5
NC
—§
0.9
1.3
NC
0.4
0.7
NC
0
1.6
I
FOV-040
2.2
No
No
No
6.1
<2.5
D
0.8
0.6
NC
14.1
15.5
NC
1.0
1.8
NC
3.9
7.2
NC
FOV-041
18.3
Yes
No
Yes
8.6
3.6
D
0.8
0.5
NC
2.1
2.3
NC
0.1
0.1
NC
0
0
NC
FOV-042
>37
Yes
No
No
4.0
4.0
NC
0.3
0.1
D
0.3
0.4
NC
0.1
0.1
NC
0
0
NC
FOV-043
29.2
Yes
Yes
Yes
2.9
4.6
NC
0.2
0.3
NC
13.4
1.3
D
2.0
0.3
D
12.5
0
D
FOV-044
19.6
Yes
Yes
Yes
10.4
2.9
D
0.1
0.2
I
1.0
10.1
I
0.0
1.3
I
0
0
NC
FOV-045
8.3
Yes
Yes
Yes
6.3
5.5
NC
0.2
0.3
NC
1.6
18.8
I
0.7
3.6
I
1.8
10.7
I
FOV-046
6.6
Yes
Yes
No
3.7
<2.5
NC
0.3
0.1
D
21.0
16.0
NC
3.8
4.1
NC
11.4
17.1
NC
FOV-047
>35.5
Yes
Yes
Yes
8.7
3.8
D
0.5
0.8
NC
6.3
1.6
D
0.4
0.2
D
16.3
1.4
D
FOV-048
4.7
Yes
No
No
7.0
<2.5
D
0.5
0.3
NC
21.9
18.3
NC
3.9
4.9
NC
2.1
17.6
I
FOV-049
22.0
Yes
No
Yes
6.6
4.8
NC
1
0.7
NC
4.2
2.6
NC
0.2
0.4
I
0
0
NC
†‡§Blood samples of patients were collected before (pre) and after (post) the 1st cycle of vaccination, and HMGB1 and other biomarkers were measured. Response criteria of IgG, CTL, and epitope spreading were previously reported; post values were compared with prevalues, and if the postvalue was ≥150% or ≤50% of prevalue, it was considered increased or decreased, respectively. I: increased; D: decreased; NC: no change; samples were not available.
